Article Text

other Versions

PDF
Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs
  1. Federica Corallini1,
  2. Paola Secchiero1,
  3. Gabriella Castellino2,
  4. Maurizio Montecucco3,
  5. Francesco Trotta2,
  6. Giorgio Zauli1,4
  1. 1Department of Morphology and Embryology, University of Ferrara, Ferrara, Italy
  2. 2Rheumatology Section, Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy
  3. 3Department of Rheumatology, IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy
  4. 4IRCCS, Burlo Garofolo Hospital, Trieste, Italy
  1. Correspondence to Professor Giorgio Zauli, Department of Morphology and Embryology, University of Ferrara, Via Fossato di Mortara 66, 44100 Ferrara, Italy; giorgio.zauli{at}unife.it

Statistics from Altmetric.com

Products of the secreted frizzled-related protein (FRZB) families have crucial roles in the development and maintenance of bone, cartilage and joints, mainly by inhibiting the wnt and/β catenin pathway.1 In particular, while several important studies have associated FRZB (also known as sFRP3) with an increased susceptibility to the development of osteoarthritis,2,,4 no information is available on the potential role of circulating FRZB in early rheumatoid arthritis (ERA).

We have measured the serum levels of FRZB by ELISA (R&D Systems, Minneapolis, Minnesota, USA) in a cohort of patients presenting with ERA, defined as previously described.5 Serological signs of inflammation (raised erythrocyte sedimentation rate or C reactive …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.